In a recent subgroup analysis study by Dinardo et al. [52], it was discovered that among AML patients receiving venetoclax-based therapies, the strongest molecular associations with response were found to be present in patients with mutations in genes such as IDH1, IDH2, NPM1, and DNMT3A. Here, IDH1 is linked to acute myeloid leukemia.